Shimoda, Yukiko
Yoshida, Tatsuya
Miyakoshi, Jun
Torasawa, Masahiro
Tateishi, Akiko
Matsumoto, Yuji
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Yamamoto, Noboru
Ohe, Yuichiro
Article History
Received: 7 November 2022
Accepted: 19 March 2023
First Online: 16 April 2023
Declarations
:
: Dr. Yoshida received grants and personal fees from AstraZeneca and Bristol-Myers Squibb; grants from AbbVie, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical; and personal fees from Chugai and Novartis. Dr. Matsumoto received grants from Grant-in-Aid for Scientific Research on Innovative Areas, Hitachi High-Technologies, Hitachi, Ltd., and National Cancer Center Research and Development Fund and received personal fees from AMCO INC., AstraZeneca, COOK, and Olympus. Dr. Masuda received personal fees from Chugai and AstraZeneca. Dr. Shinno received personal fees from Pfizer, AstraZeneca, and Chugai Pharmaceutical and received grants from Japan Clinical Research Operations K.K., Janssen Pharmaceutical K.K., and Ono Pharmaceutical. Dr. Okuma received grants from AbbVie. Dr. Goto received grants and personal fees from Bristol-Myers Squibb, Daiichi- Sankyo, Eli Lilly, Guardant Health, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical; grants from Kyorin; and personal fees from AstraZeneca, Boehringer Ingelheim, Chugai, and Illumina. Dr. Horinouchi received grants and personal fees from AstraZeneca, BMS, Chugai, Eli Lilly, MSD, Taiho Pharmaceutical, and Ono Pharmaceutical and received grants from Astellas, Genomic Health, and Merck Serono. Dr. Yamamoto received grants and personal fees from BMS, Boehringer Ingelheim, Chugai, Eisai, Eli Lilly, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical; grants from Astellas, Bayer, Chiome Bioscience Inc., Daiichi-Sankyo, GSK, Janssen Pharma, Kyowa-Hakko kirin, MSD, Merck, Novartis, Otsuka, Taiho Pharmaceutical, Quintiles, and Sumitomo Dainippon; and received personal fees from AstraZeneca, Otsuka, Cimic, and Sysmex. Dr. Ohe received grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly, Janssen Pharma, Kyorin, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Takeda Pharmaceutical; grants from Kissei; and personal fees from Boehringer Ingelheim, and Celtrion. The remaining authors declare no competing interests.
: The present study with human samples has been approved by the Ethics Committee of the National Cancer Center Hospital, Tokyo, Japan (2019-123).